Roche’s Alzheimer’s Drug Fails In Phase III Giving Eisai/Biogen A Clear Run
Fails To Produce Significant Slowing Of Disease
Executive Summary
Roche’s gantenerumab has failed to make the grade in its GRADUATE studies, leaving the field wide open for Eisai and Biogen’s lecanemab.
You may also be interested in...
How Much Amyloid Clearance, How Fast Is Needed To Slow Alzheimer’s?
Lilly’s donanemab showed faster, deeper amyloid clearance versus Biogen/Eisai’s Aduhelm and Roche’s failed Phase III gantenerumab studies showed the importance of deep, rapid removal.
Eisai/Biogen’s Lecanemab Effective Across Endpoints, But Will Safety Limit Use?
Alzheimer’s patients treated with the amyloid protofibril-clearing antibody had slower disease progression compared to placebo, with differences increasing over time. Safety concerns, however, are growing.
CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure
Phase III results for Eisai/Biogen’s lecanemab are the main event at the Clinical Trials on Alzheimer’s Disease meeting, but other data – even Roche’s failed Phase III gantenerumab studies – also may have implications for the amyloid-clearing antibody.